Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [615]

Addition of docetaxel to initial hormone therapy substantially improves...

Dr Michael Carducci - Johns Hopkins School of Medicine, Baltimore, USA

Addition of docetaxel to initial hormone therapy substantially improves survival in metastatic, hormone-sensitive prostate cancer ( Dr Michael Carducci - Johns Hopkins School of Medicine, Baltimore, USA )

Addition of docetaxel to initial hormone therapy substantially improves...

Prof Christopher Sweeney - Dana-Farber Cancer Institute, Boston, USA

Addition of docetaxel to initial hormone therapy substantially improves survival in metastatic, hormone-sensitive prostate cancer ( Prof Christopher Sweeney - Dana-Farber Cancer Institute, Boston, USA )

ASCO 2014: Advances in prostate cancer discussion

Prof Noel Clarke; Dr Cora Sternberg; Dr Kurt Miller, Prof Wysocki

ASCO 2014: Advances in prostate cancer discussion ( Prof Noel Clarke; Dr Cora Sternberg; Dr Kurt Miller, Prof Wysocki )

Addition of docetaxel to initial hormone therapy substantially improves...

Prof Christopher Sweeney - Dana-Farber Cancer Institute, Boston, USA

Addition of docetaxel to initial hormone therapy substantially improves survival in metastatic, hormone-sensitive prostate cancer ( Prof Christopher Sweeney - Dana-Farber Cancer Institute, Boston, USA )

Adjuvant exemestane more effective than tamoxifen when combined with ovarian...

Dr Olivia Pagani - Oncology Institute of Southern Switzerland, Bellinzona...

Adjuvant exemestane more effective than tamoxifen when combined with ovarian function suppression in young women with hormone-sensitive, early-stage breast cancer ( Dr Olivia Pagani - Oncology Institute of Southern Switzerland, Bellinzona, Switzerland )

Adjuvant exemestane is more effective than tamoxifen when combined with ovarian...

Dr Olivia Pagani - Oncology Institute of Southern Switzerland, Bellinzona...

Adjuvant exemestane is more effective than tamoxifen when combined with ovarian function suppression in young women with hormone-sensitive, early-stage breast cancer ( Dr Olivia Pagani - Oncology Institute of Southern Switzerland, Bellinzona, Switzerland )

Comment: Advances in breast cancer presented at ASCO 2014

Prof Jacek Jassem - Gdańsk Medical University, Gdańsk, Poland

Comment: Advances in breast cancer presented at ASCO 2014 ( Prof Jacek Jassem - Gdańsk Medical University, Gdańsk, Poland )

Medyczne nowości w raku gruczołu krokowego

Prof Piotr Jan Wysocki - Poznan University of Medical Sciences, Poznan, Poland

Medyczne nowości w raku gruczołu krokowego ( Prof Piotr Jan Wysocki - Poznan University of Medical Sciences, Poznan, Poland )

Upcoming trends in myeloma therapy

Dr Kenneth Anderson; Prof Gareth Morgan; Prof Paul Richardson

Upcoming trends in myeloma therapy ( Dr Kenneth Anderson; Prof Gareth Morgan; Prof Paul Richardson )

Lecture: Current use of systemic therapies in localised disease

Dr Rainy Umbas - University of Indonesia, Jakarta, Indonesia

Lecture: Current use of systemic therapies in localised disease ( Dr Rainy Umbas - University of Indonesia, Jakarta, Indonesia )

Lecture: Current standard of care in advanced disease

Dr Wayne YH Chang - National Yang-Ming University Taipei, Taiwan

Lecture: Current standard of care in advanced disease ( Dr Wayne YH Chang - National Yang-Ming University Taipei, Taiwan )

Lecture: Exploring the androgen signalling pathway in CRPC

Dr Paul de Souza - University of Western Sydney, New South Wales, Australia

Lecture: Exploring the androgen signalling pathway in CRPC ( Dr Paul de Souza - University of Western Sydney, New South Wales, Australia )

More from ecancer